Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Biologic Agents are Being Used Earlier and More Often to Treat Rheumatoid Arthritis in the EU5, According to Two Recent Reports



  Biologic Agents are Being Used Earlier and More Often to Treat Rheumatoid
  Arthritis in the EU5, According to Two Recent Reports from BioTrends

Business Wire

EXTON, Pa. -- December 06, 2012

BioTrends Research Group, one of the world’s leading research and advisory
firms for specialized biopharmaceutical issues, finds that in their two latest
EU5 reports on rheumatoid arthritis (RA), there have been some changes in the
way that biologics are used to treat RA patients in the past year. According
to TreatmentTrends: Rheumatoid Arthritis (EU) 2012, most surveyed EU5
physicians indicate their use of biologic agents to treat their RA patients
has increased, and they are also initiating biologic therapy earlier and being
more aggressive with these agents. Further, in the past year, the newer
biologics, some with a different mechanism of action, are taking share from
the more established ones. ChartTrends: Rheumatoid Arthritis (EU) 2012 finds
that in a review of patient charts, the majority of RA patients continue to
take Pfizer/Amgen’s Enbrel and Abbott’s Humira for first line biologic
therapy. For second line therapy, Biogen Idec/Roche’s MabThera is used by 51
percent of patients. Suboptimal response and no response are the top reasons
EU5 physicians discontinued first line biologic therapy for their RA patients,
after waiting approximately 15 months before discontinuing for suboptimal
response and 6.5 months with no response.

“The recent approval of Bristol-Myers Squibb’s Orencia SC and expected future
approval of Roche/Genentech’s RoActemra SC could also increase the use of
biologics in the EU5,” said BioTrends Immunology Therapeutic Class Director
Paul Zimmerman. “The real fun will begin once Pfizer’s tofacitinib is approved
in the EU5, assuming the label is similar to the one in the U.S., and
physicians find a place for this product in their treatment algorithm.”

TreatmentTrends: Rheumatoid Arthritis (EU) 2012 is an annual, quantitative
publication that examines current trends in the management of RA from the
perspective of rheumatologists with a focus on analyzing their attitudes,
perceptions, and self-reported prescribing behavior. In addition, this report
provides insight into practice patterns, and current and projected use of
various products. TreatmentTrends also evaluates perceived product advantages
and disadvantages, as well as sales and messaging efforts of key market
players. This report was fielded with 273 rheumatologists in France, Germany,
Italy, Spain, and the UK in September 2012 via an on-line survey.

ChartTrends: Rheumatoid Arthritis (EU) 2012 is an annual, quantitative
publication based on patient and laboratory data collected from 1,150 RA
patient charts provided by 284 rheumatologists in August - September 2012 in
France, Germany, Italy, Spain, and the UK. Through an in-depth review of
specific patient charts, details such as product dosing and titration,
switching, concomitant medications and a host of laboratory and patient
demographic variables help define patient types and identify therapy triggers.
All collection methods were designed in compliance with local country privacy
regulations.

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market
research to pharmaceutical manufacturers competing in clinically evolving,
specialty pharmaceutical markets. For information on BioTrends publications
and research capabilities, please contact us at (610) 321-9400 or
www.bio-trends.com. BioTrends is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers
best-in-class, high-value information and insights on important sectors of the
healthcare industry. Clients rely on this analysis and data to make informed
decisions. Please visit Decision Resources Group
at www.DecisionResourcesGroup.com.

    All company, brand, or product names contained in this document may be
                   trademarks of their respective holders.

Contact:

BioTrends Research Group, LLC
Paul Zimmerman, 610-321-9427
pzimmerman@bio-trends.com
or
Decision Resources Group
Christopher Comfort, 781-993-2597
ccomfort@dresources.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement